Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Moderate Buy” from Brokerages
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating on the […]
